A Phase 2 interventional study of Low Dose Naltrexone in Vulvodynia, sponsored by University of Florida. Not yet recruiting at 2 sites in United States. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by University of Florida · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Vulvodynia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Vulvodynia · United States.
Among the 47 studies in Vulvodynia with a site in United States, this one is the 25th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2027, is one of 10 in phase 2, and was the 47th registered.
117 studies on the registry are indexed under Vulvodynia; 21 are open to participants now.
Browse Vulvodynia studies →8 of the 47 studies in Vulvodynia with a site in United States are open now. Recruiting first, the newest first:
Center for Vulvovaginal Disorders · Sites in United States
Ages 18+ · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
Center for Vulvovaginal Disorders · Sites in United States
Ages 18+ · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
Texas Tech University Health Sciences Center · Sites in United States
Ages 21–75 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Vulvodynia studies recruiting now, 8 (62%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 99 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 5 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 46 across 89 interventional studies indexed under Vulvodynia.
Median enrollment 45 across the 36 interventional studies, 168 across the 11 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 47 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 1 study filed under Vulvodynia — fewer than ten, so there is no comparison to draw.
6 of the studies in Vulvodynia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486830Center for Vulvovaginal DisordersIncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction | 2026-12-20 |
| NCT07401134University of MiamiImproving Postoperative Recovery: A Study of Multimodal Perineal Analgesia Protocol (MPAP) After Vaginal Surgery | 2027-01 |
| NCT05343182Oregon Health and Science UniversityVestibulectomy Surgical Techniques Comparison Study | 2027-04 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
| NCT01829204Texas Tech University Health Sciences CenterProspective Data Bank Creation to Study Vaginal Conditions | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 47 studies in Vulvodynia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational pilot study is to assess the safety, efficacy, and tolerability of oral low dose naltrexone (LDN) in the treatment of vulvodynia. The aims it will address are:
Aim 1:To assess the efficacy of LDN by reviewing patient-reported Global Treatment Improvement scale scores after the 4-week treatment period.
Aim 2: To identify the impact on overall and vulvar pain by calculating the difference between average pre- and post-treatment PGIC, NRS, CSI and VPAQ scores.
Aim 3: To identify adverse effects that patients may experience during treatment to better understand the safety profile of this medication.
Participants will [describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items]
Vulvodynia is a chronic vulvar pain condition characterized by persistent vulvar pain or discomfort without an identifiable cause. The condition can substantially affect quality of life, including sexual function, emotional well-being, and social functioning. The etiology of vulvodynia is multifactorial and may involve peripheral nerve dysfunction, hormonal factors, pelvic floor dysfunction, and altered central pain processing.
Available treatments for vulvodynia include topical medications, pelvic floor physical therapy, systemic medications, behavioral interventions, injections, and other procedural therapies. Treatment response is variable, and some participants continue to experience clinically significant symptoms despite conventional management. Additional treatment options with acceptable tolerability are therefore needed.
Low-dose naltrexone (LDN) is a low-dose formulation of naltrexone that has been investigated for the management of several chronic pain conditions. Proposed mechanisms include modulation of neuroinflammatory pathways and reduction of inflammatory signaling within the central nervous system. The potential effects of LDN on vulvodynia-related pain remain insufficiently characterized, supporting further clinical investigation.
This pilot study will evaluate the safety, tolerability, and potential effectiveness of oral LDN for the treatment of vulvodynia. The study will enroll approximately 20 adult female participants with vulvodynia. Participants will receive oral LDN at a dose of 4.5 mg once daily for four weeks.
The study will consist of screening, a four-week treatment period, and post-treatment follow-up. Screening procedures will include confirmation of eligibility, collection of demographic and clinical information, medication review, pregnancy testing when applicable, assessment of baseline pain and symptoms, and laboratory testing. Baseline assessment will include a comprehensive clinical evaluation and validated measures of pain and vulvodynia-related symptoms. A pelvic floor and vulvar assessment will be performed as clinically appropriate and according to the study protocol.
Before initiation of LDN, participants will record daily vulvar pain scores for seven consecutive days using the Numerical Rating Scale (NRS). The average baseline NRS score will be calculated from the seven-day recording period. Validated questionnaires will also be administered at baseline and during follow-up to assess vulvar pain, symptom severity, treatment-related improvement, and central sensitization.
Following completion of baseline assessments, LDN will be dispensed through a mail-order pharmacy. Participants will take 4.5 mg orally once daily for four weeks. Medication instructions and information regarding potential adverse effects will be provided before treatment initiation.
Safety monitoring will occur throughout the treatment period. Participants will be instructed to discontinue study medication and contact the study team promptly in the event of significant or concerning adverse reactions. A study coordinator will conduct an adverse-event and adherence assessment approximately two weeks after treatment initiation. A follow-up clinical assessment will occur approximately four weeks after treatment initiation.
Safety laboratory testing will include a complete blood count and comprehensive metabolic panel at screening and at the end of treatment. Hepatic enzymes, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin, will be assessed at baseline and at the end of treatment and may be repeated when clinically indicated. Treatment-emergent liver enzyme elevations will be followed until resolution or stabilization, as clinically appropriate. Other treatment-emergent adverse events will be monitored until resolution or stabilization.
Participants will be counseled regarding the potential risks associated with naltrexone, including dizziness, somnolence, fatigue, gastrointestinal symptoms, hypersensitivity reactions, mood-related adverse effects, and potential hepatic injury. Counseling will also address the importance of avoiding opioid-containing medications during treatment and the potential risk of opioid withdrawal and opioid overdose following naltrexone exposure. Participants of childbearing potential will receive pregnancy and contraception counseling consistent with the study eligibility requirements and protocol.
The study will include assessment of adherence, treatment-related adverse effects, and changes in pain and symptom measures from baseline to follow-up. Patient-reported treatment improvement will be assessed using the designated global treatment improvement measure. Changes in average NRS and vulvar pain questionnaire scores will also be evaluated.
The study will use descriptive statistics to characterize baseline participant and clinical data. Pre-treatment and post-treatment pain and symptom scores will be compared using appropriate statistical methods. A two-sided alpha level of 0.05 will be used to define statistical significance for inferential analyses. Given the pilot nature and anticipated sample size of approximately 20 participants, analyses will primarily provide estimates of treatment response, variability, and tolerability to inform the design of future studies.
Research procedures will be distinguished from standard clinical care. Routine medical history, physical examination, and clinically indicated pelvic or vulvar evaluation may occur as part of standard clinical care. Study-specific procedures include administration of oral LDN, study-specific questionnaires and assessments, systematic adverse-event monitoring, study-specific follow-up assessments, and collection and analysis of research data.
Study data will be collected and maintained in accordance with applicable institutional policies, regulatory requirements, and privacy protections. Research data will be coded or de-identified as appropriate. Data shared with collaborating investigators at Mayo Clinic may include coded or de-identified demographic, clinical, treatment-response, and adverse-event information. Direct identifiers will not be included in data sets intended for research analysis unless specifically permitted under applicable institutional and regulatory requirements. Data transfers will occur through secure institutional systems, and access will be limited to authorized research personnel. Data retention and destruction will follow institutional requirements, applicable regulations, and the approved study data-management plan.
The study is planned to recruit approximately 20 participants. Recruitment and data collection are anticipated during Quarters 1 through 3 of 2027, followed by data analysis during Quarter 4 of 2027. The anticipated deliverable is a pilot assessment of the safety, tolerability, and potential effectiveness of LDN for vulvodynia. Findings from the pilot study are intended to provide preliminary data regarding treatment response and adverse events and may inform the design and feasibility of a subsequent larger clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4.5 mg oral LDN daily for four weeks
Drug: Low Dose Naltrexone
4.5 mg oral LDN daily for four weeks
Patient Global Impression of Change
Primary outcome is the overall improvement in participant's vulvar pain symptoms as assessed by the Patient Global Impression of Change (PGIC) after four weeks of treatment. It is a single question assessment to measure how much a health condition has changed after treatment. Scale 1-7 (1= best outcome, 7 =worst outcome).
Time frame: 4 weeks
Numerical Rating Scale
Net change in Numerical Rating Scale (NRS) after four weeks of treatment. NRS allows patients to rate their pain on a scale of 0-10 (0 =no pain, 10= most severe pain).
Time frame: 4 weeks
Vulvar Pain Assessment Questionnaire
Net change in Vulvar Pain Assessment Questionnaire (VPAQ) after four weeks of treatment. 38 item questionnaire that uses a 5-point Likert Scale (0-4 with 0= no symptoms 4=worst symptoms)
Time frame: 4 weeks
CSI
Net change in Central Sensitization Inventory (CSI) after four weeks of treatment. Consists of 25 health-related questions with possible responses on a 5-point Likert scale (0-4 with 0=never and 4=always). Total score out of 100 with higher number reflecting a worse outcome.
Time frame: 4 weeks
Plan to share: No — Individual participant data will not be made available to outside researchers to protect participant privacy and comply with the institutional consent framework governing this study. Aggregated data supporting the study findings will be published in the manuscript and supplementary files.
Start is estimated for Jan 2027; primary completion for Jul 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naltrexone